MariTide vs Retatrutide: Molecular Design, Receptors, and Trial Evidence
Direct answer: MariTide and retatrutide are different investigational molecules, not two names for the same peptide. MariTide, or maridebart cafraglutide, is an antibody–peptide conjugate that antagonizes the GIP receptor while activating the GLP-1 receptor. Retatrutide is a single acylated peptide that activates the GIP, GLP-1, and glucagon receptors. Both have been studied in obesity trials, but no published head-to-head trial establishes that one is superior to the other.
The receptor comparison needs direction, not just a target list
Writing that both candidates “target GIP and GLP-1” hides the most important mechanistic difference. The original AMG 133 design study describes a fully human GIP-receptor antagonist antibody linked to two GLP-1 agonist peptides. The antibody component and attached peptides give MariTide a molecular architecture that is fundamentally different from a free peptide agonist.
Retatrutide is described in its Phase 2 primary report as a triple agonist at the GIP, GLP-1, and glucagon receptors. GIP-receptor antagonism and GIP-receptor agonism are opposite directions of modulation. A target name alone therefore cannot support a claim that the two candidates work the same way.
For background on how assay context changes receptor comparisons, see the Retatrutide, Tirzepatide, and Semaglutide receptor-assay guide.
Evidence map: what can actually be compared?
| Comparison field | MariTide | Retatrutide | Interpretation boundary |
|---|---|---|---|
| Molecular format | GIPR-antagonist monoclonal antibody conjugated to two GLP-1 agonist peptides | Single acylated peptide | Manufacturing, disposition, and analytical identity cannot be transferred between formats |
| Receptor direction | GIPR antagonism plus GLP-1R agonism | GIPR, GLP-1R, and GCGR agonism | Sharing receptor names does not mean sharing signaling direction |
| Published Phase 2 design | Randomized placebo-controlled study; 592 participants across obesity cohorts with and without type 2 diabetes | Randomized placebo-controlled study; 338 adults with obesity or overweight without diabetes | Separate populations, schedules, estimands, and follow-up prevent a direct efficacy ranking |
| Primary outcome | Percent change in body weight at week 52 | Percent change in body weight at week 24, with further assessment through week 48 | Different time points and protocols must remain visible |
| Head-to-head evidence | None identified in the cited primary reports | None identified in the cited primary reports | Cross-trial percentages are not a substitute for randomization within one protocol |
The published MariTide Phase 2 trial tested several schedules and enrolled separate cohorts with and without type 2 diabetes. The retatrutide report used a different dose-ranging protocol and population. This independently assembled comparison shows why placing the largest percentage from each paper in one ranking table would erase design differences rather than clarify them.
Trial results do not identify a catalog material
A clinical paper identifies the intervention used under that protocol. It does not authenticate an unrelated vial or establish that a catalog lot has the same formulation, purity, exposure, or performance. A Retatrutide research material must be evaluated through its own specification and lot documentation, while the GLP-1 Peptides collection is only a navigation layer.
The retatrutide research-context guide separates receptor, animal, and clinical evidence. The survodutide versus retatrutide comparison provides another example of matching trial populations and endpoints before interpreting numerical differences. Batch documents, when available, belong in the NEXTWAVE PEPTIDES COA library, not in a clinical-outcome comparison.
Research limitations
This article compares published molecular and trial records. It does not conduct a new experiment, reproduce either sponsor’s assays, recommend treatment, or compare individual outcomes. The human trials were not designed as a head-to-head comparison, and their results should not be treated as if participants had been randomized between MariTide and retatrutide. Development programs and registry records can also change after publication.
Frequently asked questions
Is MariTide another name for retatrutide?
No. MariTide is the development name for maridebart cafraglutide, an antibody–peptide conjugate. Retatrutide is a separate triple-receptor agonist peptide.
Do both candidates activate the GIP receptor?
No. Published design records describe MariTide as antagonizing GIPR, whereas retatrutide agonizes GIPR along with GLP-1R and GCGR.
Can the Phase 2 weight-change percentages be directly ranked?
Not defensibly. The studies used different populations, schedules, time points, estimands, and protocols. A valid superiority claim would require an appropriately designed direct comparison.
Are either trial results proof about a research vial?
No. Trial results apply to the specified intervention and protocol. A separate material requires its own identity, specification, and lot records.